New medicine for rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/rare diseases, and the orphan drug panorama has advanced drastically since then. […]
New medicine for rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/rare diseases, and the orphan drug panorama has advanced drastically since then. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline.
MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases on 9th -10th July 2020, will provide a valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers will describe how their analysis journeys have developed the response towards up-to-date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
Ergomed and PSR Orphan Experts are looking forward being a part of this event and invite you to meet up with our team online. Contact are details below:
- Alex Artyomenko, Head of Rare Disease and RWE Research Alex.Artyomenko@ergomedgroup.com
- Christa van Kan, Strategic Director Rare Diseases christa.vankan@psr-group.com
- Jonathan Pritchard, Director, Business Development Jonathan.Pritchard@ergomedgroup.com
Or you can reach us by emailing: info@psr-group.com or info@ergomedgroup.com
